Navigation Links
Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac
Date:10/8/2009

iCardiac Extends #1 Worldwide Market Position in Automated QT Studies

Rochester, New York (PRWEB) October 8, 2009 -- iCardiac Technologies, Inc., a global leader in advanced cardiac core lab services and QT analysis, announced today that an international pharmaceutical company has awarded iCardiac a comprehensive cardiac safety study. iCardiac will provide end-to-end study management, equipment deployment and scientific reporting, as well as advanced ECG analytics. The study will utilize iCardiac's Highly Automated QT(sm) and Dynamic QT beat-to-beat(sm) service offerings to dramatically improve study precision and reduce false positives and negatives.

"We are pleased that the industry's worldwide adoption of iCardiac's automated QT methods continues to accelerate," said Sasha Latypova, Executive Vice President. "With this contract award it is clear that the industry is transiting to more advanced methods for cardiac safety evaluation and that iCardiac is leading this transition."

In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision, high rate of false positives/negatives and high cost of the "gold standard" manual or semi-automated QT measurements has lead to efforts toward providing more advanced cardiac safety analytics.

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically-differentiated global cardiac core lab providing the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies for Phase I through Phase IV studies, supported by expert scientific consultation, end-to-end project management, worldwide site and equipment logistics, 24/7 customer support and regulatory data submission. iCardiac's analysis services provide drug developers with more precise and cost-effective methods for ECG interval measurements, including Highly Automated QT, which is the market leading solution for automated evaluation of QT intervals for regulatory submissions. In addition, iCardiac provides Beyond QTsm, a suite of advanced ECG-based cardiac safety markers that have been accepted and used as a secondary end-point in regulatory approvals, and which delivers a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology and medical device companies. For more information, visit: www.icardiac.com.

# # #

Read the full story at http://www.prweb.com/releases/automated/tqt/prweb3005784.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Global Experts Explore Entire Spectrum of Aids Vaccine Development
2. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
3. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
4. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs
7. Jazz Pharmaceuticals to Present at UBS Global Life Sciences Conference
8. A Large-Scale Research Project by a Dutch Consortium Addressing a Global Problem
9. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
10. Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference
11. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/2/2019)... ... October 31, 2019 , ... Join ... in a live webinar on Friday, November 15, 2019 at 1pm ... Immunosequencing, the science of profiling T-cell receptors (TCRs) and B-cell receptors (BCRs), has ...
(Date:10/30/2019)... ... , ... While using cold plasma to kill cancer cells isn’t an entirely ... Mines & Technology are exploring new ways to regulate cold plasma technology to ... the technique would prove to be a drug-free, minimally invasive cancer treatment that would ...
(Date:10/29/2019)... ... October 28, 2019 , ... CaroGen Corporation , ... , Professor Jack R Wands, MD, of Brown University , ... , Professor Gil Mor, MD, PhD, of Wayne State University, formerly a ...
(Date:10/29/2019)... Mass. (PRWEB) , ... October 29, 2019 , ... ... spectral signature of the skin*. Using Silios CMS-C multispectral imagers , researchers ... new approach can replace identification based on retinal imaging, face recognition, fingerprints and ...
Breaking Biology Technology:
(Date:12/4/2019)... N.Y. (PRWEB) , ... December 04, 2019 , ... ... aesthetics companies today, has launched Subnovii Advanced Plasma Technology for U.S. ... breakthrough portfolio, Subnovii is the only plasma to employ LF technology – low ...
(Date:11/27/2019)... , ... November 26, 2019 , ... ... to their Glen Ellyn, IL practice for Invisalign® treatment. Invisalign orthodontics ... , Patients with a misaligned bite, also known as malocclusion, present both functional ...
(Date:11/22/2019)... ... November 21, 2019 , ... The inventors of a new ... a major step forward with that therapy, known as SurVaxM. MimiVax LLC principals ... off from Roswell Park in 2012, has entered into a China-exclusive licensing agreement ...
Breaking Biology News(10 mins):